Inborn errors of metabolism:
Indications for: ELELYSO
Long-term enzyme replacement therapy (ERT) for patients with confirmed Type 1 Gaucher disease.
Adults and Children:
<4yrs: not established. Consider premedication with antihistamines and/or corticosteroids. Give by IV infusion over 60–120 minutes. ≥4yrs: 60 Units/kg once every 2 weeks. Begin treatment with Elelyso at the same dose when switching from imiglucerase.
ELELYSO Warnings/Precautions:
Have appropriate medical support available. Closely monitor patients during and after the infusion. Discontinue immediately if severe hypersensitivity reactions including anaphylaxis occur and treat appropriately. Reduce or temporarily interrupt infusion, or administer antihistamines, corticosteroids and/or antipyretics if hypersensitivity reactions occur. Monitor for development of anti-drug antibodies. Pregnancy. Nursing mothers.
ELELYSO Classification:
Lysosomal glucocerebroside-specific enzyme.
Adverse Reactions:
Headache, arthralgia, fatigue, nausea, dizziness, abdominal pain, pruritus, flushing, vomiting, urticaria, extremity pain.
Drug Elimination:
Half-life: Pediatric: 37.1 minutes (range: 22.5–56.8); Adult: 18.9 minutes (range: 9.20–57.9).
Generic Drug Availability:
NO
How Supplied:
Single-use vial—1
